2018
DOI: 10.1016/j.bjm.2018.02.004
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: This study examined the antimicrobial susceptibility patterns and clonal complex (CC) characteristics of serogroup 6 Streptococcus pneumoniae isolates collected from children in Beijing, China, between 1997 and 2016. Serotypes were determined using the Quellung reaction, and the antimicrobial susceptibility profiles of the isolates were determined using the disc-diffusion method or by E-test. Sequence types (STs) were assigned based on multilocus sequence typing. A total of 250 isolates were examined, with 55.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 26 publications
0
2
0
Order By: Relevance
“…Monoclonal antibodies could be used as an alternative therapy for patients not responding to conventional antibiotics or as a preventive drug for patients being at risk for developing systemic complications. In our study we showed that mAbs directed against serogroup 6, one of the most prevalent serogroups worldwide (82,83), were effective in preventing systemic pneumococcal infection. This and the fact that some serotype 6 variants are poorly immunogenic, makes this serogroup a relevant strain for development of mAbs.…”
Section: Discussionmentioning
confidence: 62%
“…Monoclonal antibodies could be used as an alternative therapy for patients not responding to conventional antibiotics or as a preventive drug for patients being at risk for developing systemic complications. In our study we showed that mAbs directed against serogroup 6, one of the most prevalent serogroups worldwide (82,83), were effective in preventing systemic pneumococcal infection. This and the fact that some serotype 6 variants are poorly immunogenic, makes this serogroup a relevant strain for development of mAbs.…”
Section: Discussionmentioning
confidence: 62%
“…Overall, the presented work provides a proof of concept not only for the capacity of hexamer-enhancing mutations to improve anti-capsule mAb-meditated immune system activation, but also for the potential use of monoclonal antibodies against encapsulated bacteria like S. pneumoniae when the existing therapies fail. In this study, we demonstrated that the activity of mAbs directed against serogroup 6 , one of the most prevalent serogroups worldwide ( Shi et al, 2018 ; van der Linden et al, 2013 ), could be effectively improved to prevent systemic pneumococcal infection. Furthermore, the fact that CPS6 mAbs likely cross-react with the highly invasive 19A strain, for which of invasive infection rates increased following PCV7 use worldwide ( Aguiar et al, 2010 ), suggests the potential broader use of monoclonal antibodies.…”
Section: Discussionmentioning
confidence: 89%